Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology
Healthcare
$2.18 -6.49%
-$0.30 today
- Market cap
- $108.64M
- Beta
- -0.11
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.46
52W Low $1.76High $12.46
Volume 0.28M
Average 0.21M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$13.51B
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$74.45B
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.91M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Depreciation & Amortization | 101.79K | 8.51K | 30.98K | 22.47K | 5.44M |
| Deferred Income Tax | (1.8M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.22M | 4.11M | 1.97M | 1.33M | 1.33B |
| Change in Working Capital | 259.34K | (4.06M) | 4.94M | (320.6K) | (632.35K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 857.6K | (883.55K) | 835.65K | (197.48K) | (1.06M) |
| Other Working Capital | (598.27K) | (3.18M) | 4.1M | (123.13K) | 426.67K |
| Other Non-Cash Items | 21.53M | 7.41M | 8.28M | (22.02M) | (14.55B) |
| Operating Cash Flow | (24.6M) | (24.65M) | (14.78M) | (19.55M) | (13.51B) |
| Capital Expenditures | 0 | (16.33K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (16.33K) | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 20M | 0 | 74.45M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 60M | (5) | (396.29K) | 0 | 74.38B |
| Financing Cash Flow | 60M | (5) | 19.6M | 0 | 74.45B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 35.4M | (24.66M) | 4.82M | (19.55M) | 60.94B |
| Free Cash Flow | (24.6M) | (24.66M) | (14.78M) | (19.55M) | (13.51B) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$293.4M
+ D&A$5.4M
+ Stock-Based Comp$1.3B
+ Deferred Tax$0
- Working Capital-$632.3K
- Other Non-Cash-$14.5B
= Operating Cash Flow-$13.5B
- Capex$0
= Free Cash Flow-$13.5B
Analysis
FY2025 free cash flow is -$13.5B. FCF conversion is 4604.6% of net income. Operating cash flow was -$13.5B, with capex of $0. The largest bridge item is Other Non-Cash at -$14.5B.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| 10-Q | Quarterly report | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 |
Does NERV generate free cash flow?
Minerva Neurosciences, Inc. (NERV) generated -$13.51B of free cash flow in fiscal 2025.
How much operating cash flow does NERV produce?
Operating cash flow was -$13.51B, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.